Loading...
Loading...
Celgene International Sàrl, a wholly-owned subsidiary of Celgene
Corporation
CELG today announced that results from an ad hoc
analysis of a subset of subjects with higher-risk myelodysplastic
syndrome (MDS) from two ongoing phase I/II studies of oral epigenetic
agent CC-486 (oral azacitidine) were presented at the American Society
of Hematology annual meeting in New Orleans, La.
In this analysis, 23 patients with WHO-defined RAEB-1 or RAEB-2 MDS who
received CC-486 300mg once per day (n=20) or 200mg twice per day (n=3)
for 14 or 21 days of repeated 28-day cycles. For purposes of this
analysis, subject data were analyzed collectively. Hematologic responses
were defined by International Working Group (IWG) 2006 criteria. Overall
response rate
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in